Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Analyzing the Growth Rate of the Cardiac Amyloidosis Market: What’s the Expected CAGR for the Next Decade?

In recent times, the market size for cardiac amyloidosis has experienced robust growth. An increase from $5.26 billion in 2024 to $5.75 billion in 2025 is projected, with a compound annual growth rate (CAGR) of 9.2%. This historic growth can be credited to factors such as the increased prevalence of conditions linked to amyloidosis, a rise in genetic mutation cases, enhanced awareness, a surge in instances of transthyretin amyloidosis, and an expanding elderly population.

Expectations are high for significant expansion of the cardiac amyloidosis market in the approaching years. The projected valuation is anticipated to reach $8.10 billion by 2029, with a compound annual growth rate (CAGR) of 9.0%. Factors contributing to this growth during the projected period include heightened diagnostic rates, government-backed initiatives, an increase in the occurrence of genetic mutations, and the implementation of patient assistance programs. The forecast period is also expected to witness major trends such as the emergence of novel treatments like vulrisiran, an increased focus on gene therapy research, precision medicine, advances in diagnostic technologies, and the inception of unique therapies.

What Factors Are Propelling the Growth of the Cardiac Amyloidosis Market from 2025 to 2034?

The growth of the cardiac amyloidosis market is anticipated to be driven by the increasing elderly population. Essentially, this term pertains to individuals who are generally 65 years old or older and might need specialized healthcare assistance due to age-related variations. The rise in this demographic is a result of higher life expectancy, improvements in healthcare, and decreasing birth rates. As a significant risk factor for amyloid protein build-up in the heart is aging, the growing geriatric population augments the prevalence of cardiac amyloidosis. To illustrate, data from the Population Reference Bureau, a nonprofit organization based in the US, demonstrated in January 2024 that the US population aged 65 and older is projected to surge from 58 million in 2022 to 82 million by 2050, signifying a 47% increase. Consequently, the growing number of elderly people will stimulate the expansion of the cardiac amyloidosis market.

Explore Comprehensive Insights Into The Global Cardiac Amyloidosis Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21128&type=smp

What are the leading organizations impacting the Cardiac Amyloidosis market’s growth?

Major companies operating in the cardiac amyloidosis market are Pfizer Inc., Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Alexion Pharmaceuticals Inc., Dr. Reddy’s Laboratories, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., BridgeBio Pharma Inc., Prothena Corp, Intellia Therapeutics Inc., Amylyx Pharmaceuticals, Neurimmune AG, SOM Biotech, Oncopeptides, Attralus Inc., Eidos Therapeutics.

What Are the Most Prominent Trends Driving Change in the Cardiac Amyloidosis Market?

Leading corporations in the cardiac amyloidosis market are prioritizing technological advancements like AI-powered software-only diagnostic instruments to improve early detection and enhance patient outcomes for this often-missed disease. A diagnostic apparatus using artificial intelligence, capable of analysing echocardiographic images to detect cardiac amyloidosis signs without needing extra hardware or extensive clinical data. For example, Ultromics Ltd., a UK-based healthcare technology firm, received FDA approval for EchoGo Amyloidosis, an AI-enabled clinical instrument for early detection of cardiac amyloidosis, in November 2024. This device is the first to receive marketing authorization from the FDA’s Total Product Lifecycle Advisory Program (TAP). EchoGo Amyloidosis harnesses the power of artificial intelligence to analyze echocardiograms, detecting the disease from a single clip and meeting the critical need for earlier diagnosis before it silently advances.

Secure Your Global Cardiac Amyloidosis Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/cardiac-amyloidosis-global-market-report

What Are the Core Segments of the Cardiac Amyloidosis Market, and How Do They Contribute to Growth?

The cardiac amyloidosis market covered in this report is segmented –

1) By Product Type: Light Chain Amyloidosis, Transthyretin Amyloidosis

2) By Treatment: Chemotherapy, Surgery, Supportive Care, Stem Cell Transplant, Targeted Therapy

3) By End-User: Hospitals, Ambulatory Surgical Centres, Clinics

Subsegments:

1) By Light Chain Amyloidosis: Immunoglobulin Light Chain (AL) Amyloidosis, Primary Light Chain Amyloidosis, Secondary Light Chain Amyloidosis

2) By Transthyretin Amyloidosis: Hereditary Transthyretin Amyloidosis (ATTRm), Wild-type Transthyretin Amyloidosis (ATTRwt)

What Regions Are Leading the Charge in the Cardiac Amyloidosis Market?

North America was the largest region in the cardiac amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Is the Cardiac Amyloidosis Market Categorized and Defined in the Industry?

Cardiac amyloidosis is a condition where abnormal amyloid protein deposits in the heart tissue, leading to stiffening and impaired function. This results in heart failure, arrhythmias, and other cardiovascular complications. Early diagnosis and treatment are crucial to managing symptoms and slowing disease progression.

Browse Through More Similar Reports By The Business Research Company:

Aminoglycosides Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/aminoglycosides-global-market-report

Glycomics or Glycobiology Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/glycomics-or-glycobiology-global-market-report

Smart Insulin Pens Global Market Report 2025

https://thebusinessresearchcompany.com/report/smart-insulin-pens-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: